Barclays initiated coverage of Charles River with an Equal Weight rating and $230 price target. The analyst says near-term market disruptions and potential recovery delays could put the company’s margin guidance at risk. The firm has “limited near-term visibility on market stability to make a call one way or another.” Longer term, it believes Charles River has a sound business and finds it likely just a matter of timing before the stock’s multiples recover.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River announces strategic collaboration with Gates Institute
- ‘The CRO Sector Looks Appealing,’ Says Goldman Sachs — Here Are 2 Stocks to Consider
- Charles River, Captain T Cell in plasmid DNA-Viral Vector alliance
- Charles River in collaboration with MatTek awarded $1.3M grant from FCRI
- Charles River initiated with a Neutral at Mizuho